PDS Biotechnology
PDSB
52 hedge funds and large institutions have $182M invested in PDS Biotechnology in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 26 increasing their positions, 8 reducing their positions, and 4 closing their positions.
225% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 8
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
23% more capital invested
Capital invested by funds: $148M → $182M (+$33.9M)
2.52% more ownership
Funds ownership: 0% → 2.52% (+2.5%)
2% more funds holding
Funds holding: 51 → 52 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.83M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$811K |
| 3 |
Goldman Sachs
New York
|
+$328K |
| 4 |
Franklin Resources
San Mateo,
California
|
+$327K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$298K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Asset Management One
Tokyo,
Japan
|
-$2.31M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$1.29M |
| 3 |
RC
RegentAtlantic Capital
Morristown,
New Jersey
|
-$234K |
| 4 |
TG
TLP Group
Evanston,
Illinois
|
-$102K |
| 5 |
MWP
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
|
-$56K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Barclays
London,
United Kingdom
| $5K | +$3.41K | +15 | +300% |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| $1K | -$21.8K | -96 | -97% |
|
|
53
Asset Management One
Tokyo,
Japan
| – | -$2.31M | -11,189 | Closed |
|
|
RC
54
RegentAtlantic Capital
Morristown,
New Jersey
| – | -$234K | -1,125 | Closed |
|
|
TG
55
TLP Group
Evanston,
Illinois
| – | -$102K | -490 | Closed |
|
|
MWP
56
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
| – | -$56K | -268 | Closed |
|
PDSB Hedge Fund Activity: Q4 2016 in Review
52 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q4 2016, worth a combined $182M — up 23% from $148M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PDSB positions and 4 closed out — a net gain of 1 holder — while 26 added to existing stakes and 8 trimmed.
The largest buyer was Acuta Capital Partners, adding an estimated $3.83M. The largest seller was Asset Management One, exiting entirely with an estimated $2.31M sold.
- 52 institutional investors held PDS Biotechnology (PDSB) as of Q4 2016, up from 51 in Q3 2016.
- Funds reported $182M of PDS Biotechnology stock for Q4 2016, up 23% quarter-over-quarter.
- 5 funds opened new PDS Biotechnology positions in Q4 2016 and 4 closed out, a net change of +1 holder.
- The largest PDS Biotechnology buyer in Q4 2016 was Acuta Capital Partners, an estimated $3.83M added.
- The largest PDS Biotechnology seller in Q4 2016 was Asset Management One, an estimated $2.31M sold.
Based on aggregated 13F filings for Q4 2016.